Posts Tagged “synthetic cannabis”

HempCon San Bernardino 2014 –  OCT 17-19, 2014

San Bernardino – NOS Events Center
OCT 17-19, 2014

3:00pm – 9:00pm
11:00am – 9:00pm
11:00am – 7:00pm

689 South E. St. San Bernardino, CA

What you’ll find

Grow Products
Legal Services
Doctor’s Evaluation


Contact info: 626.961.6522

GLASS & VAPE SHOW | HOLLYWOOD, FL Sunday, October 19, 2014 10:00 AM to 6:00 PM

If you are in South Florida, plan on coming to the Glass and Vape Show at the HardRock. The Glass & Vape Show is a one-day retail shopping expo featuring 50 of the best glassblowers, glass retailers and vaporizer brands from around the region.


Register Here

Got to Love It – NBA Players DeAndre Jordan, Matt Barnes & Glen Davis Got Stoned in Amsterdam

The NBA doesn’t test for weed in the offseason, so some Los Angeles Clippers decided to capitalize on their freedom.According to TMZ, teammates DeAndre Jordan, Matt Barnes, and Glen Davis are (or were just) vacationing in Amsterdam.

The three were photographed smoking what looks clearly like either a joint or a spliff at one of Amsterdam’s legendary coffee shops. As the following photos indicate, DeAndre caught the apple-pipe of the Paparazzi’s eyes.

While Jordan appears to be the leader of this European getaway, the trio rolled deep with an entourage, and looks completely stress free.

I can’t quite tell what Coffee Shop they’re at, but Matt Barnes’ case of the Chinese eyes indicates whatever they smoked clearly worked:


Then Barnes got the standard post-blaze paranoia, while Glen Davis’ sweatshirt turned into a baby-T:


Next, DeAndre did what everyone wants to do after a nice Hybrid:


dumpser hump

Two days ago, Wiz Khalifa posted this photo to Instagram with DeAndre and Barnes

wiz jordan

When in Amsterdam…

This Map Shows You Which Countries Smoke the Most Pot

The Washington Post created a convenient data map based on the United Nations 2014 World Drug Report.

In the U.S. cannabis is the most popular illegal substance and almost half of all Americans have tried it. In case you’ve ever wondered which countries smoke the most pot, the Washington Postcreated a convenient data map based on the  United Nations 2014 World Drug Report.

According to the map, Iceland wins the prize for most stoners per capita with 55,000 pot users total (almost 1/4 of their population). According to the Washington Post, Iceland’s president wants to follow in Uruguay’s pioneering footsteps and legalize.

“If we allow the sale of alcohol,”  he said, “there is no reason to ban the soft drugs any longer.”

In its article describing their data map, theWashington Post included a significant caveat: “There are huge swath’s of the globe where there is no data, so it’s difficult to know how much weed is smoked there. For instance, in Southeast Asia,  home to the happy pizza, little data is to be had.”

What they were able to map is worth a gander, however, so check out the Washington Post data map “Measuring global cannabis use” below:

Click here for a larger image

georgiaforcannabisGeorgia to study legalizing medical marijuana

See Origional Post at the The Atlanta Journal-Constitution

Georgia lawmakers are moving ahead with plans to study the legalization of medical marijuana.

General Assembly leaders began this week to appoint committee members charged with making recommendations on the issue, after the state House and Senate failed to reach a compromise in the waning hours of this year’s legislative session. State Rep. Allen Peake, R-Macon, will lead the committee along with Senate Health and Human Services Chairwoman Renee Unterman, R-Buford.

The appointments come amid a flurry of announcements from the state Capitol over assignments to a number of panels. Some study committees spend state money to look into issues of debatable value, such as self-driving cars. Others will tackle serious issues, such as the state’s controversial attempts to store water in underground aquifers.

In the House, Speaker David Ralston, R-Blue Ridge, named lawmakers to panels that will study ride-sharing services like Uber and Lyft, as well as how the state compensates people who are wrongfully convicted of crimes.

Several joint House and Senate study committees have yet to be named, including ones that will study transportation issues and the Common Core education initiative.

Peake led the push earlier this year to legalize limited use of medical marijuana in Georgia. His legislation, House Bill 885, would allow Georgia families to use cannabis oil to treat certain seizure disorders in both children and adults, afflictions that can cause hundreds of seizures a day and often lead to death.

The oil is harvested from the marijuana plant but does not create the high that other forms of marijuana produce. The bill would have provided immunity from prosecution to anyone who was in possession of the particular cannabis oil the bill wants to make legal.

It also would have cleared the way for patients and their parents to travel outside of Georgia to find a supply, most likely in Colorado because it allows the oil’s use in limited amounts.

HB 885 found support in both chambers, but failed when the Senate — led by Unterman — tied it to efforts requiring insurance companies to cover behavioral therapy for children 6 and under who have been diagnosed with autism.

The committee has not yet scheduled meeting dates, but is expected to issue a report by year’s end.

30 Members Of Congress Demand Increased Access To Marijuana For Research Purposes

Thirty members of Congress, led by Reps. Earl Blumenauer (D-Ore.), H. Morgan Griffith (R-Va.), Dana Rohrabacher (R-Calif.) and Jan Schakowsky (D-Ill.), sent a letter to Health and Human Services Secretary Sylvia Burwell on Tuesday demanding an end to the federal monopoly on marijuana research so that more studies can be done by scientists around the nation.


“We write to express our support for increasing scientific research on the therapeutic risks and benefits of marijuana,” the letter reads. “We ask that you take measures to ensure that any non-National Institutes of Health (NIH) funded researcher who has acquired necessary Food and Drug Administration (FDA), Institutional Review Board (IRB), Drug Enforcement Administration (DEA) and appropriate state and local authority approval be able to access marijuana for research at-cost without further review.” (Read the full text of the letter below.)

The letter comes about two weeks after the House voted to block the Drug Enforcement Administration from using funds to go after medical marijuana operations that are legal under state laws, a measure that Rohrabacher sponsored.

And just last week, a scathing joint report from the Drug Policy Alliance and and the Multidisciplinary Association for Psychedelic Studies blasted the DEA, arguing that the agency has repeatedly failed to act in a timely fashion when faced with petitions to reschedule marijuana.

The drug is currently illegal under federal law, and remains classified as a Schedule I substance, a designation the DEA reserves for the “most dangerous” drugs with “no currently accepted medical use.” Schedule I drugs, which include substances like heroin and LSD, cannot receive federal funding for research. On three separate occasions — in 1973, 1995 and 2002 — the DEA took years to make a final decision about a rescheduling petition, and in two of those cases the DEA was sued multiple times to force a decision.

Last week’s report criticized the DEA for overruling its own officials charged with determining how illicit substances should be scheduled. It also accused the agency of creating a “regulatory Catch-22” by arguing there is not enough scientific evidence to support rescheduling marijuana — while simultaneously impeding the research that would produce such evidence.

“Two weeks ago, we took a very important vote in the House to stop the DEA from interfering in states’ medical marijuana programs,” Blumenauer said in a statement Tuesday. “Now we need the Administration to stop targeting marijuana above and beyond other drugs when it comes to research. By increasing access for scientists who are conducting studies, we end the Catch-22 of opponents claiming they can’t support medical marijuana because there’s not enough research, but blocking research because they don’t support medical marijuana.”

The U.S. government grows marijuana for research purposes at the University of Mississippi in the only federally legal marijuana garden in the U.S. The National Institute on Drug Abuse (NIDA) oversees the cultivation, production and distribution of these crops — a process through which the only federally-sanctioned marijuana studies are approved.

Federal authorities have long been accused of only funding marijuana research that focuses on the potential negative effects of the drug. Since 2003, more than 500 grants for marijuana-related studies have received federal approval, with a marked upswing in recent years, according to McClatchy. Only 22 grants were approved in 2003 for cannabis research, totaling $6 million, but in 2012, 69 grants were approved for a total of over $30 million.

Despite these numbers, NIDA has reportedly conducted only about 30 studies to date on the potential benefits of marijuana, according to The Hill.

Currently, 22 states and the District of Columbia have legalized marijuana for medical use. Eight other states — Alabama, Iowa, Kentucky, Mississippi, South Carolina, Tennessee, Utah and Wisconsin — have legalized CBD oil, a non-psychoactive ingredient in marijuana that is frequently used to treat epilepsy, for limited medical use or for research purposes.

A number of studies in recent years have shown the medical potential of cannabis. Purified forms may attack some forms of aggressive cancer. Marijuana use has also been tied to better blood sugar control and may help slow the spread of HIV. One study found that legalization of the plant for medical purposes may even lead to lower suicide rates.

Read the full letter below:

Dear Secretary Burwell,

We write to express our support for increasing scientific research on the therapeutic risks and benefits of marijuana. We ask that you take measures to ensure that any non-National Institutes of Health (NIH) funded researcher who has acquired necessary Food and Drug Administration (FDA), Institutional Review Board (IRB), Drug Enforcement Administration (DEA) and appropriate state and local authority approval be able to access marijuana for research at-cost without further review.

Twenty-two states and the District of Columbia have passed laws allowing for the use of medical marijuana. Over one million Americans currently use medical marijuana at the recommendation of their physician. There is overwhelming anecdotal evidence from patients, their family members, and their doctors of the therapeutic benefits of marijuana for those suffering from cancer, epilepsy, seizures, Post-Traumatic Stress Disorder, glaucoma, anxiety, chronic pain, and more.

We believe the widespread use of medical marijuana should necessitate research into what specific relief it offers and how it can best be delivered for different people and different conditions. Yet, the scientific research clearly documenting these benefits has often been hampered by federal barriers.

Researchers seeking to develop prescription drugs in the United States must go through FDA and IRB approval processes. To conduct research using Schedule I substances such as marijuana, LSD, psilocybin and MDMA, researchers must also seek a DEA registration, as well as any required state and local licenses. The review process required to gain these approvals is robust and ensures that researchers are weighing the risks as well as the possible benefits of their potential medications.

Only with marijuana, and no other Schedule I substances, is there an additional Public Health Service review for non NIH-funded protocols, established in the May 21, 1999, Department of Health and Human Services (HHS) “Guidance on Procedures for the Provision of Marijuana for Medical Research[1].” This review process grants access to the only source of marijuana that can be legally used for research – grown by the University of Mississippi under contract with the National Institute on Drug Abuse (NIDA).

In light of the fact that substances like opioids and barbiturates have been researched and developed for human use, it would seem that we should investigate the legitimate medical uses of marijuana. We request that you review and revise the HHS Guidance to eliminate what we believe to be an unnecessary additional review process. NIDA should provide marijuana at-cost to all non-NIH funded marijuana research protocols that have successfully obtained necessary FDA, DEA, IRB and appropriate state and local authority approval.

Considering the number of states with medical marijuana laws and the number of patients who use marijuana medicinally in the United States, it is clear that we need more scientific information about the therapeutic risks and benefits of marijuana.

Thank you for your attention to this request, and we look forward to your response.

Lack of education behind opposition to cannabis – medical marijuana – legalization

Proponents of cannabis – medical marijuana – law reform say a lack of education and a lack of conversation are behind growing opposition to the legalization of cannabis.

A survey by the Otago University Students’ Association has found 52 percent of students are opposed to full legalisation, after the recent controversies surrounding synthetic highs.

But NORML president Chris Fowlie says the harms caused by synthetic cannabis are the most powerful argument yet for the legalization of natural cannabis.

“The only way to stop it happening is to legally regulate and control real cannabis.

“That is the only way to keep synthetic cannabis out.” Synthetic Cannabis is Not Medical Marijuana


What is Synthetic Marijuana?

Popular belief is that synthetic marijuana is safe, non-toxic, and elicits a psychoactive (mind-altering) effect similar to regular marijuana. However, case reports and surveys have identified serious toxicities that occur with use of synthetic marijuana, and some users have required emergency room treatment. The chemicals synthesized for the production of synthetic pot can be more potent than natural THC found in marijuana, and may have more dangerous side effects. Little is known of the pharmacological profile of the chemicals or their by-products.